Curriculum Vitae

ARTHUR V. PRANCAN, Ph.D.
312 919-1061
avprancan@gmail.com

Review Date: June 1, 2020

Education:

B.S. (Zoology) 1968
Butler University
Indianapolis, Indiana

Ph.D. (Physiology and Biophysics) 1973
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma

Trainee of the US Public Health Service Cardiovascular Physiology and Pharmacology Training Program (HL 05859), 1970-73
Departments of Pharmacology and Medicine, and of the Department of Physiology and Biophysics, University of Oklahoma Health Sciences Center

Academic Appointments:

Instructor, 1973-74
Section of Pharmacogenetics
Department of Internal Medicine
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois

Assistant Professor, 1974-84
Department of Pharmacology
Rush Medical College
1653 West Congress Parkway
Chicago, Illinois 60612

Associate Professor, 1984-2009
Department of Pharmacology, Rush Medical College

Associate Professor, 2009 - Present
Pharmacology and Physiology
Department of Basic Biomedical Sciences
Touro College of Osteopathic Medicine

Honors:

Schweppe Fellow, 1975 - present
Schweppe Foundation Research Fellowship
The Schweppe Foundation
211 East Chicago Avenue
Chicago, Illinois 60611
Pasteur Fellow, 1978 - present
Institut Pasteur
Rue du Dr. Roux
Paris, Cedex 15, France

Basic Science Faculty Award, 2006
Dr. William M. Scholl College of Podiatric Medicine
The Mark H. Lepper, M.D. Society of Teachers Award

Student's Choice Award for Excellence in Teaching, June 7, 2007
Rush University Graduate College

The Student's Choice Award for Excellence in Teaching, May 8, 2009
Class of 2011
Touro College of Osteopathic Medicine

Administrative Appointments:

FoundingDirector, Pharmacology Ph.D. Program,1977-1981
Graduate School, College of Health Sciences, Rush University

Founding Director, Division of Pharmacology, 1981-1997
Ph.D. Program, 2 M.S. Programs
The Graduate College, Rush University

Course Director, Independent Study - Medical Pharmacology, 1974-76
Course Director, Advanced Topics in Pharmacology, 1977-85
Course Director, Independent Study - Medical Pharmacology, 1979-81
Course Director, Experimental Models in Research, 1979-85
Course Director, Pharmacology, Alternative Curriculum, 1984-85
Course Director, Advanced Pharmacology (NUR 529), College of Nursing, 1986-91
Course Director, Graduate Student Colloquium, 1993-94
Course Director, Medical Pharmacology, 1994-2009
Course Director, Summer Medical Pharmacology, 1994-2003
Course Director, Introduction to Physiology and Pharmacology 2005 – 2009
Course Director, Advanced Pharmacokinetics, 2005-2009
Course Director, Toxicology, 2008-2009
Department of Pharmacology
Rush Medical College
Rush Graduate College
Rush University

Visiting Lecturer, 1995-2000
Scholl College of Podiatry, Chicago

Visiting Lecturer, 2000-2002
Scholl College of Podiatric Medicine
Physicians Assistant Program
Finch University, North Chicago, Illinois

Visiting Lecturer, 2002-2009
Scholl College of Podiatric Medicine
Physicians Assistant Program
Rosalind Franklin University, North Chicago

Visiting Lecturer, 2004
St Matthew's University College of Medicine, Grand Cayman, BWI

Visiting Lecturer, 2007
Ross University College of Medicine, Dominica, WI

Acting Chairman, 1995-1997
Department of Pharmacology, Rush Medical College

Associate Chairman, 1999-2005
Department of Pharmacology, Rush Medical College

Assistant Dean, 2004-2009
The Graduate College, Rush University Medical Center

Founding Director, MS in Biotechnology, 2005-2009
The Graduate College, Rush University Medical Center

Visiting Lecturer, 2008-2009
Malcom X College, Chicago

Co-Course Director, 2008-2009
Principal Lecturer Pharmacology I and II
Touro College of Osteopathic Medicine, New York

Course Director, 2009–2014, 2016-2018
Pharmacology I and II
Touro College of Osteopathic Medicine

Course Director, 2009-2014
Problem Based Learning
Introduction to Cultural Competence in Healthcare
Touro College of Osteopathic Medicine

Chairman, 2009–2013
Department of Basic Biomedical Sciences
Touro College of Osteopathic Medicine

Director Master of Science, 2010 - Present
Interdisciplinary Studies in Biological and Physical Sciences
Touro College

Interim Preclinical Dean, 2013 – 2014
Touro College of Osteopathic Medicine

Preclinical Dean, 2014 – Present
Touro College of Osteopathic Medicine

Hospital Appointments:

Assistant Scientist, 1973-84
Department of Internal Medicine
Rush-Presbyterian-St. Luke's Medical Center, Chicago

Associate Scientist, 1984-2009
Department of Internal Medicine
Rush-Presbyterian-St. Luke's Medical Center, Chicago

External Organizations:

Sigma Xi (Rush University Chapter), 2006 - Present
Vice President , 2006-2007
President, 2007-2009

American Society for Pharmacology and Experimental Therapeutics (ASPET)
1974 - Present
Great Lakes Chapter - ASPET
Secretary, 1997-1999
Vice President, 1999-2001
President, 2001- 2003
Past President, 2003-2005
Councilor, 2005-2009

National Association of Minority Medical Educators, 2010 – Present

American Association for the Advancement of Science (AAAS), Present

Internal Organizations:

Rush-Presbyterian-St. Luke's Medical Center:
Human Investigation Committee, 1981-85

Institutional Review Board (IRB)
Rush University Medical Center
Member and Acting Chairman, 1998-2009

Department of Pharmacology
Rush University Medical Center
Human Research Safety Monitoring Committee
Originator and Chairman 2000 - 2001

IRB Subcommittee - Safety Monitoring Committee, 2001-2009
Originator and Chairman
Rush University Medical Center

Rush University:
Commencement Committee, 1977-78
Ad Hoc Committee for Revision of Rules for Governance, Secretary, 1978-81
University Scheduling Task Force, 1980-1990
University Council, 1983-1997
Task Force on Rush University Research Forum, 1995-2009

Graduate College Study Group, Chairman, 2007-2008

Higher Learning Commission
North Central Association for Colleges and Schools
Rush University Visit in 2008

Rush Medical College:
Committee on Senior Faculty Appointments and Promotions,1975-78
Committee on Research, 1975-78 (Chairman 1976-78)
Committee on Educational Appraisal, 1982-1986
(Chairman 1983-1986)
Committee on Student Evaluation and Promotions, 1986-1989
Task Force on Investigation/Authorship Guidelines, 1995-96
Task Force on M.D.- Ph.D., 1995-97
Steering Committee, M.D.-Ph.D., 1997-2009
Task Force on Development of Faculty as Teachers, 1998-2002
Task Force on Curricular Renewal, 1998-2002
Curriculum Committee, 2004-2005
Curriculum and Evaluation Committee, 2005-2009

Rush Graduate College:
Executive Committee, 1981-84
Graduate College Council, 1984-1997

Rush College of Health Sciences:
Committee on Appointments, 1976-78
Graduate School Executive Committee, 1976-81
Ad Hoc Committee for Revision of Policies and Procedures for Rules for Governance, 1978-81

Rush Department of Pharmacology:
Advisory Committee, 1973-2009

Rush Graduate Division of Pharmacology:
Admissions Committee (Chairman, 1977-1997)
Advisory Committee (Chairman, 1977-1997)

Touro College of Osteopathic Medicine:
Admissions Interviewer, 2009-Present
Student Promotions Committee, 2009-Present
Curriculum Committee, 2009–Present
Research Committee, 2009-present
Institutional Review Board, 2010–2019
Institutional Animal Care and Use Committee (Chairman, 2010–present)
Dean's Council, 2013-Present

Conference Organization:

Co-Chairman, Session on Prostaglandins,
Fall Meeting, American Society for Pharmacology and Experimental Therapeutics, Montreal, Quebec, Canada, Aug., 1974.
Chairman,Prostaglandins, Midwest Pharmacology Conference
The Chicago Medical School, North Chicago, Illinois, May, 1981

Chairman, Inflammation, Great Lakes Chapter of ASPET
Rush-Presbyterian-St. Luke's Medical Center, June 10, 2002

Research Support: The Schweppe Foundation
The Role of Prostaglandins in E.coli Endotoxin Shock
1975-78, $30,000

Rush University Committee on Research
Methylprednisolone and Indomethacin on Plasma
Prostaglandin Concentration During Endotoxin Shock
1975-76, $4,200

NIH, National Heart, Lung and Blood Institute
Control of Platelet Aggregation in Shock
1978-80, $33,500

Rush University Committee on Research
Prostacyclin in Experimental Diabetes
1980-81, $5,729

Rush University Committee on Research
Tissue Sources of Thromboxane and Prostacyclin During
Endotoxin Shock
1983-84, $4,191

Rush University Committee on Research
Aortic Prostacyclin and Platelet Thromboxane Production in the
Diabetic Chinese Hamster
1984-86, $6,137

Rush University Committee on Research
Platelet Activating Factor as a Mediator of Endotoxin Shock
1987-89, $9,282

American Heart Association
Mechanism of Cyclosporine Induced Hypotension
1987-89, $54,870

Rush University Committee on Research
Peripheral Metabolic Elimination of Cortisol Inhibited by Insulin
1991-92, $9,956

Publications:

1. Nakano, J and Prancan, AV: Metabolic degradation of prostaglandin E1 in rat plasma and in rat brain, heart, lung, kidney and testicle homogenates. J. Pharm. Pharmacol. 23:231-232, 1971.

2. Nakano, J, Prancan, AV and Moore, SE: Metabolism of prostaglandin E1 in the cerebral cortex and cerebellum of the dog and rat. Brain Res. 39:545-548, 1972.

3. Nakano, J and Prancan, AV: Effects of the adrenergic blockages on the cardiovascular responses to ethanol and acetaldehyde. Arch. Int. Pharmacodyn. 196:259-268, 1972.
4. Nakano, J and Prancan, AV: Effect of prostaglandins E1 and A1 on the gastric circulation in dogs. Proc. Soc. Exp. Biol. Med. 139:1151-1154, 1972.

5. Prancan, AV and Nakano, J: Effect of pyrazole on conversion of ethanol and acetate into lipids in rat liver. Res. Comm. Clin. Pathol. Pharmacol. 4:181-191, 1972.

6. McCurdy, JR, Greenfield, LJ, Prancan, AV and Nakano, J: Cardiovascular, hematological and metabolic effects of prostaglandin E1 in endotoxin shock. Circulation. 46:1-186, 1972.
7. Nakano, J, McCloy, RB and Prancan, AV: Circulatory and pulmonary airway pressure responses to different mixtures of prostaglandins E2 and F2 in dogs, Europ. J. Pharmacol. 24:61-66, 1973.

8. Nakano, J and Prancan, AV: Metabolic degradation of prostaglandin E1 in the lung and kidney of rats in endotoxin shock. Proc. Soc. Exp. Biol. Med. 144:506-508, 1973.

9. Nakano, J, Prancan, AV and Morsey, NLH: Metabolism of prostaglandin E1 in stomach, jejunum chyle and plasma of the dog and the rat. Jap. J. Pharmacol. 23:355-361, 1973.

10. Benjamin, B, Alaupovic, P, Wang, CS, Prancan, AV and Hinshaw, LB: Relationship of chemical structure to patho-physiological properties of endotoxin from serratia marcescens. Circulatory Shock 1 1:61-69, 1974.

11. McCloy, RB, Prancan, AV and Nakano, J: Effects of acetaldehyde on the systemic, pulmonary and regional circulations. Cardiovas. Res. 8:216-226, 1974.

12. Prancan, AV, Lefort, J, Chignard, MM, Gerozissis, K, Dray, F and Vargaftig, BB: L8027 and 1-nonyl-imidazole as nonselective inhibitors of thromboxane synthesis. Europ. J. Pharmacol. 60:287-297, 1979.

13. Vargaftig, BB, Lefort, J, Prancan, AV, Chignard, M and Benveniste, J: Platelet-lung in vivo interactions: An artifact of a multi-purpose model. Hemostasis. 8:171-182, 1979.

14. Chignard, M, Prancan, AV, Lefort, J, Dray, F and Vargaftig, BB: Arachidonate-mediated bronchoconstriction and platelet activation are inhibited by microgram doses of compound L8027 which are not selective for thromboxane synthetase. In: Arachidonic Acid Metabolism in Inflammation and Thrombosis. Brune and Baggiolini. Birkhauser Verlag Basel. 184-187, 1979.

15. Prancan, AV, Ecanow, B, Bernardoni, RJ and Sadove, M: Poloxamer 188 as vehicle for injectable diazepam. J. Pharmaceutical Sciences. 69:970-971, 1980.

16. Prancan, AV, Simon, D and Pope, L: Platelet thromboxane production during endotoxin shock. Agents and Actions . 6/7:648-650, 1981.

17. Prancan, AV, Simon, D and Pope, L: Platelet thromboxane production during endotoxin shock. In: Pharmacology of Inflammation and Allergy. Eds. F Fusso-Marie, BB Vargaftig, J Benveniste. Elsevier Biomedical Press. 100:539-542, 1981.

18. Prancan, AV, Lefort, J, Barton, M and Vargaftig, BB: Relaxation of the guinea pig trachea induced by platelet activating factor and by serotonin. Europ. J. Pharmacol. 80:29-35, 1982.

19. Simpson, RM, Prancan, AV, Izzi, JM, and Fiedel, BA: Generation of thromboxane A2 and aorta-contracting activity from platelets stimulated with modified C-reactive protein. Immunology. 47:193-202, 1982.
20. Fried, W, Morley, C, Barone-Varelas, J, Bidani, A, and Prancan, AV: Effects of indomethacin and of prostaglandins on extrarenal erythropoietin production in rats. J. Lab. Clin. Med. 111:184-188, 1988.

21. Parkhurst, G, Moon, B, Xia, R, Littleton, M, and Prancan, AV: Cyclosporin-Induced Hypotension. Transplantation. 48:756-759, 1989.

22. Parkhurst, GW, Prancan, AV and Moon, BH: Alpha adrenergic antagonism by cyclosporine. Transplantation. 51:1080-1084, 1991.

23. Kornel, L, Prancan, AV, Kanamarlapudi, N, Hynes, J and Kuzianik, E: Study on the mechanisms of glucocorticoid-induced hypertension: glucocorticoids increase transmembrane Ca^{2+} influx in vascular smooth muscle InVivo. Endocrine Research. 21(1&2):203-10, 1995.

24. Kornel, L and Prancan, AV: Mechanism of Primary Hypertension. Harefuah, Journal of the Israel Medical Association. 134(11):837-843, 1998.

25. Lomiguen, C, Vidal, L, Kozlowski, P, Prancan, A, Stern, R: Possible Role of Chitin-Like Proteins in the Etiology of Alzheimer's Disease. J. Alzheimers Dis.66(2):439-444, 2018.

Abstracts:

1. Nakano, J, Kessinger, JM and Prancan, AV: Cardiovascular effects of ethanol and the adrenergic mechanism. Clin. Res. 19:24, 1971.

2. Nakano, J, Kessinger, JM and Prancan, AV: Cardiovascular effects of acetaldehyde in dogs. Clin. Res. 19:117, 1971.

3. Nakano, J, Prancan, AV and Kessinger, JM: Effect of prostaglandins E1 and A1 on the gastric circulation in dogs. Clin. Res. 19:399, 1971.

4. Prancan, AV and Nakano, J: Effect of pyrazole on conversion of ethanol and acetate into lipids in rat liver. Pharmacologist. 13:276, 1971.

5. Nakano, J and Prancan, AV: Relationship between structure of prostaglandins and their vasoactivity in dogs. Pharmacologist. 13:292, 1971.

6. Nakano, J, Prancan, AV and Kessinger, CL: Metabolism of prostaglandin E1 (PGE1) by cerebral and cerebellar homogenates. Proc. Cent. Soc. Clin. Res. 44:100, 1971.

7. Nakano, J and Prancan, AV: Effect of acute hypoxia and renal arterial constriction on the metabolism of prostaglandin E1 in the dog renal medulla. Clin. Res. 20:603, 1972.

8. Nakano, J, Prancan, AV, McCurdy, JR and Greenfield, LJ: Effects of prostaglandin E1 on the cardiovascular, hematological and metabolic responses to endotoxin. Clin. Res. 20:859, 1972.

9. McCloy, RB, Prancan, AV and Nakano, J: Circulatory and respiratory effects of different mixtures of prostaglandins E2 and F2. Clin. Res. 21:437, 1973.

10. McCloy, RB, Prancan, AV and Nakano, J: Direct effects of ethanol and acetaldehyde on the coronary circulation and myocardial contractile force in dogs. Clin. Res. 21(4):815, 1973.

11. Nakano, J and Prancan, AV: Effect of prostaglandin E1 and indomethacin on the survival of endotoxemic mice. Clin. Res. 21(4):815, 1973.

12. McCloy, RB, Prancan, AV and Nakano, J: Cardiovascular of acetaldehyde in dogs. Clin. Res. 21(4):815, 1973.

13. Nakano, J and Prancan, AV: Prostaglandin dehydrogenase activity in shock lungs and kidneys. Clin. Res. 21(4):887, 1973.

14. Prancan, AV, Hornbrook, KR and Nakano, J: Effect of methylprednisolone on survival and on metabolic responses to E. coli endotoxin. Fed. Proc. 33(3):298, 1974.

15. Prancan, AV and Nakano, J: Effect of glucocorticoids on the prostaglandin dehydrogenase (PGDH) activity in the lung of endotoxemic rats. The Pharmacologist. 16 (2):197, 1974.

16. McKenna, R, Ahmad, T, Prancan, AV, Simon, D and Frischer, H: Lack of Inhibition of Platelet Function by 1,3-BIS (2 Chloroethyl)-1-nitrosourea (BCNU). Thrombosis and Haemostasis. 46(1):207, 1981.

17. Prancan, AV, Simon, DM, Littleton, MT, and Pope, L: Thromboxane release in endotoxin shock platelets. Circulatory Shock. 9 (2):166, 1982.

18. Prancan, AV, Lefort, J, Vargaftig, B and Barton, M: Trachea dilation mediated by PAF-acether and serotonin. The Pharmacologist. 24 (3):245, 1982.

19. Prancan, AV and Simon, D: Thromboxane and prostacyclin in the diabetic Chinese hamster. The Second World Conference on Clinical Pharmacology and Therapeutics. p. 33, Washington, D.C., July-August, 1983.

20. Littleton, M and Prancan, AV: Thromboxane A2 and the development of shock in rabbits. The Pharmacologist. 27(3):242, 1985.

21. Simon, D, Littleton, M and Prancan, AV: Prostacyclin and thromboxane in the diabetic Chinese hamster. The Pharmacologist. 27(3):315, 1985.

22. Barone-Varelas, J, Prancan, AV, Morley, J, and Fried, W: Effect of angiotensin, captopril and indomethacin on extrarenal erythropoietin production. Clinical Research. 33(pt 2):879A, 1985.

23. Prancan, AV, Xia, R, and Littleton, M: Comparison of platelet-activating factor and endotoxin infusion in rabbits. The Second International Conference on Platelet-Activating Factor and Related Alkyl Lipids. p. 151. Gattlinburg, Tennessee, October 1986.

24. Moon, B, Parkhurst, G, Xia, R and Prancan, AV: Cyclosporine-induced hypotension. Federation Proceedings. 46:1146, 1987.

25. Prancan, AV, Xia, R and Littleton, M: Comparison of platelet-activating factor and E. coli endotoxin infusion in rabbits. Circulatory Shock. 21:299, 1987.

26. Parkhurst, G, Moon, B, Xia, R and Prancan, AV: Evidence for alpha-adrenergic blockade by cyclosporine. FASEB Journal. 2(4):A-382, 1988.

27. Kornel, L and Prancan, AV: Deactivation of cortisol (F) arterial and renal tissues, which modulates F access to mineralocorticoid (MC) and glucocorticoid (GC) receptors, is effected by three enzyme systems. Abstract, In: Program of 74th Ann. Meeting of Endocrine Soc. p. 206, San Antonio, TX, 1992.

28. Kornel, L and Prancan, AV: Insulin inhibits conversion of cortisol to C_{19} -metabolites in mineralocorticoid-responsive tissues. In Abstracts of 14th Scientific Meeting of International Society Hypertension. p. S27, Madrid, 1992.

29. Kornel, L and Prancan, AV: Insulin inhibits conversion of cortisol to C_{19} -metabolites in mineralocorticoid responsive tissues. Clinical Research. 40:711A, 1992.

30. Kornel, L and Prancan, AV: Deactivation of cortisol (F) in arterial and renal tissues, which modulates F access to mineralocorticoid (MC) and glucocorticoid (GC) receptors, is effected by three enzyme systems. In Program of Satellite Symposium of the 14th Meeting of the Intern. Soc. Hypertension: The Diabetes-Hypertension Connection. p. 5, Granada, Spain, 1992.

31. Kornel, L and Prancan, AV: Insulin inhibits conversion of cortisol to C_{19} -metabolites in mineralocorticoid-responsive tissues. In Program of Satellite Symposium of the 14th Meeting of the Intern. Soc Hypertension: The Diabetes-Hypertension Connection. p. 5, Granada, Spain, 1992.

32. Kornel, L and Prancan, AV: Deactivation of cortisol (F) in arterial and renal tissues, which modulates F access to mineralocorticoid (MC) and glucocorticoid (GC) receptors, is effected by three enzyme systems. In Program of Satellite Symposium of the Ninth Intern. Congress of Endocrinology: Cellular and Molecular Biology of the Adrenal Cortex. Avignon, France, 1992.

33. Kornel, L and Prancan, AV: Cortisol is converted to 11□-Hydroxyandrostenedione in neurons of CNS. In 75th Annual Endocrine Soc. p. 217, Las Vegas, NV, 1993.

34. Kornel, L and Prancan, AV: Calcitriol, a link between circulating Ca^{2+} level and the mineralocorticoid effect of cortisol. Clin. Research. 41:666A, 1993.

35. Kornel, L and Prancan, AV: Studies on the mechanisms of primary hypertension. In Program of the First Annual Meeting of the Federation of Israeli Society for Experimental Biology (F.I.S.E.B.). Eilat, Israel, October 18, 1995.

36. Prancan, A, Easington, C, Mattoo, A, Everitt, E, Parrillo, J and Hollenberg, S.: Leukocyte rolling in rat venules invivo is reversibly promoted by oxidants. The FASEB Journal.12(5):A803, 1998.

37. Rodgers, RL and Prancan, AV: Spontaneously hypertensive rats (SHR): Cardiac performance and oxidation of glucose and palmitate after quinapril. The FASEB Journal. 13(4):A109, 1999.

38. Prancan, AV, Kornel, L, Litwack, G, Robertson, NM, Weinstein, R, Kanamarlapudi, N and Hynes, J: Mineralocorticoid and glucocorticoid receptors: evidence for distinctiveness in rabbit arteries. The FASEB Journal. 13(4):A117, 1999.

39. McGuire, S, Prancan, A, Easington, C, Parrillo, JE and Hollenberg, S.: Sensitivity of Septic Rats to Okadaic Acid-Induced Vasoconstriction. Chest. 116(4, Suppl. 2), 366S, 1999.

40. Jackson, SL, McGuire, SM, Prancan, AV, Easington, CR, Parrillo, JE and Hollenberg, SM.: Impairment of Okadaic Acid Induced Vasoconstriction in Septic Rats. Journal ofCritical Care Medicine. 27(12, Suppl.), A99, 1999.

41. McGuire, SM, Jackson, SL, Easington, CR, Parrillo, JE, Hollenberg, SM and Prancan, AV.: Okadaic Acid Reverses Arterial Hyporesponsiveness to Catecholamines in Septic Rats. Journal of Critical Care Medicine. 27(12, Suppl.), A99, 1999.

42. McGuire, SM, Prancan, AV, Jackson, SL, Easington, CR, Parrillo, JE and Hollenberg, SM.: Okadaic Acid Reverses Arterial Hyporesponsiveness to Norepinephrine in Septic Rats. The FASEB Journal. 14(4), A689, 2000.

43. Broussard, MD, Parrillo, JE, Prancan, AV and Hollenberg, SM: Inducible Nitric Oxide Synthase (iNOS) Deficient Septic Mice Show Improved Microvascular Responsiveness to Endothelin-1. The FASEB Journal. 14(4), A404, 2000.

44. Easington, CR, Prancan, AV, Parrillo, JE and Hollenberg, SM: Time Course of Microvascular Permeability in a Clinically Relevant Model of Polymicrobial Sepsis. The FASEB Journal. 15(5), A1124, 2001.

45. Prancan, A and Ali, K: Medical Pharmacology Board Scores Increase with Flipped Classroom and Video Lectures. The FASEB Journal. 32(1, Suppl.), A549.9, 2018.

46. Prancan, A, Lomiguen, C, Vidal, L and Kozlowski, P: Possible Role of Chitin-Like Proteins in the Etiology of Alzheimer's Disease. The FASEB Journal. 33(1, Suppl.), A806.12, 2019.

Chapters:

1. Prancan, AV: Respiratory and cardiovascular pharmacology. In: Chest physical therapy and pulmonary rehabilitation, an interdisciplinary approach. Ed. D Frownfelter. Yearbook Medical Publishers, Chicago, 1978.

2. Prancan, AV: Respiratory and cardiovascular drug actions. In: Principles and Practice of Cardiopulmonary Physical Therapy, 3rd Edition. Eds. D Frownfelter and E Dean. 775-787, 1996.

3. Prancan, AV: Drug Glossary. In: American Medical Association Family Medical Guide, 4th ed. John Wiley & Sons, Inc.: 1133-1149, 2004.